Want to see NGNE full AI Analyst Report?
NGNE Stock Chart & Stats
$34.90
-$0.67(-1.88%)
At close: 4:00 PM EDT
$34.90
-$0.67(-1.88%)
Day’s Range― - ―
52-Week Range$15.93 - $43.66
Previous Close$34.9
Volume161.73K
Average Volume (3M)270.69K
Market Cap
$773.04M
Enterprise Value$492.21
Total Cash (Recent Filing)$225.39M
Total Debt (Recent Filing)$8.35M
Price to Earnings (P/E)―
Beta3.11
Next Earnings
Nov 23, 2026EPS Estimate
-1.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.51
Shares Outstanding20,011,381
10 Day Avg. Volume213,349
30 Day Avg. Volume270,693
Financial Highlights & Ratios
PEG Ratio5.20
Price to Book (P/B)1.65
Price to Sales (P/S)0.00
P/FCF Ratio-5.57
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$81.83Price Target Upside134.48% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-5.51
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
NGN-401 Clinical EvidenceDurable multidomain gains and favorable tolerability strengthen NGN-401’s evidence base, supporting progression toward registrational readout and potential BLA. They improve the program’s clinical credibility, although approval remains unproven.
Registrational Trial ExecutionCompleting dosing above target gives the registrational study a defined dataset and supports the planned BLA pathway. Strong demand and absence of reported safety-limiting toxicities improve execution visibility, while efficacy still depends on follow-up and the prespecified threshold.
Cash Runway And LeverageAbout $134.8M of net proceeds and low leverage provide funding flexibility through Q1 2029, allowing continued trials and commercial-readiness work without immediate debt stress. This reduces near-term financing risk, though equity funding can dilute holders.
Bears Say
Pre-Revenue Business ModelNGNE remains pre-revenue, with TTM revenue of $0 and no commercialized product base. The company therefore depends on financing and eventual clinical success rather than recurring operating income, leaving fundamentals exposed to trial, approval, and launch risk.
Expanding Net LossesTTM net loss widened to about $111.1M from $36.3M in 2023, while gross profit remains negative. Persistent R&D and operating costs without product revenue indicate weak earnings quality and make profitability dependent on successful commercialization.
Sustained Cash BurnOperating cash flow deteriorated from -$51.4M in 2023 to -$86.2M TTM, and TTM FCF was -$87.1M. Rising cash requirements can consume the runway faster than planned and increase reliance on future equity financing.
Neurogene News
NGNE FAQ
What was Neurogene Inc.’s price range in the past 12 months?
Neurogene Inc. lowest stock price was $15.93 and its highest was $43.66 in the past 12 months.
What is Neurogene Inc.’s market cap?
Neurogene Inc.’s market cap is $773.04M.
When is Neurogene Inc.’s upcoming earnings report date?
Neurogene Inc.’s upcoming earnings report date is Nov 23, 2026 which is in 92 days.
How were Neurogene Inc.’s earnings last quarter?
Neurogene Inc. released its earnings results on Aug 11, 2026. The company reported -$1.53 earnings per share for the quarter, missing the consensus estimate of -$1.423 by -$0.107.
Is Neurogene Inc. overvalued?
According to Wall Street analysts Neurogene Inc.’s price is currently Undervalued.
Does Neurogene Inc. pay dividends?
Neurogene Inc. does not currently pay dividends.
What is Neurogene Inc.’s EPS estimate?
Neurogene Inc.’s EPS estimate is -1.33.
How many shares outstanding does Neurogene Inc. have?
Neurogene Inc. has 20,011,381 shares outstanding.
What happened to Neurogene Inc.’s price movement after its last earnings report?
Neurogene Inc. reported an EPS of -$1.53 in its last earnings report, missing expectations of -$1.423. Following the earnings report the stock price went down -2.052%.
Which hedge fund is a major shareholder of Neurogene Inc.?
Currently, no hedge funds are holding shares in NGNE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Neurogene Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$81.83 (134.48% Upside)
$81.83 (134.48% Upside)
Blogger Sentiment
Bearish
NGNE Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 252.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 16.2%
Last 30 Days ▲ 8.9%
Last 30 Days ▲ 8.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
52.37%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-17.81%
Trailing 12-Months
Company Description
Neurogene Inc.
Neurogene Inc. is dedicated to engineering transformative genetic treatments for individuals and their families grappling with debilitating neurological conditions. Its current pipeline prominently features two key investigational therapies: NGN-401, an AAV9 gene therapy specifically targeting Rett syndrome, and NGN-101, which is being developed to address neuronal ceroid lipofuscinosis subtype 5 (Batten disease). The company's operations are based in New York, New York.
NGNE Stock 12 Month Forecast
Average Price Target
$81.83
▲(134.48% Upside)
Technical Analysis
Silence Therapeutics
―
Atea Pharmaceuticals
―
Elicio Therapeutics
―
Vor Biopharma
―
Tenaya Therapeutics
―
Ownership Overview
7.35% Insiders
6.59% Mutual Funds
54.56% Other Institutional Investors
22.40% Public Companies and
Individual Investors